How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-non-small-cell-lung-cancer-with-no-anaplastic-lymphoma-kinase-genomic-tumor-aberrations.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Imjudo	TREMELIMUMAB	AstraZeneca	CTLA-4-directed Blocking Antibody [EPC]	CTLA-4		2022-01-01
IMJUDO	TREMELIMUMAB-ACTL	ASTRAZENECA AB	CTLA-4-directed Blocking Antibody [EPC]	Cytotoxic T-lymphocyte protein 4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

ASTRAZENECA AB · 1 drug in Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations
AstraZeneca · 1 drug in Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations:

Cite this brief

Drug Landscape (2026). Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-non-small-cell-lung-cancer-with-no-anaplastic-lymphoma-kinase-genomic-tumor-aberrations. Accessed 2026-06-10.

Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing